FORMYCON AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55 EUR | +1.66% |
|
-0.92% | -2.70% |
| 07-01 | US FDA Approves Formycon's Biosimilar to Treat Serious Retinal Diseases | MT |
| 06-18 | Borse Frankfurt-News: Many winners and many losers (second-line stocks) | DP |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FORMYCON AG | Other Biotechnology & Medical Research | +1.29% | -0.92% | - | - | - | 1.02B | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- FYB Stock
- FYB Stock
- Charts Formycon AG
- Comparison Chart
